AXSM
Axsome Therapeutics, Inc.
Biotechnology · Healthcare · United States
213.68
close · 2026-08-13
value
44
cheaper than peers44
quality
17
stronger fundamentals17
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
caveat margins at their own peak
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -2.2% | 77 |
| cash flow yield, 3 years ago | -1.0% | 77 |
| cash flow yield, 1 year ago | -1.1% | 59 |
| earnings yield, 1 year ago | -2.8% | 59 |
| earnings yield, 2 years ago | -2.5% | 59 |
| cash flow yield, 2 years ago | -1.3% | 59 |
| price to sales | 16.05× | 42 |
| cash flow yield, latest year | -0.8% | 41 |
| earnings yield, latest year | -1.7% | 32 |
| forward P/E | 41.99× | 18 |
| price to book | 134.14× | 1 |
11 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 57.4% | 65 |
| operating margin | -32.8% | 59 |
| debt to equity | 402.8% | 6 |
| return on equity | -349.4% | 6 |
4 of 4 measures available
Facts
| market cap | $11B |
| free cash flow | -$3.9M |
| employees | 1,220 |
| first trade | 2015-11-19 |
| next earnings | 2026-08-10 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.68 | -5.99 | -5.27 | -4.60 |
| free cash flow | -$93.9M | -$128.7M | -$145.7M | -$117.2M |
| net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M |
| revenue | $638.5M | $385.7M | $270.6M | $50.0M |
| unusual items | -$7.9M | -$28.1M | -$48.9M | -$3.3M |